Pennine Acute Hospitals NHS Trust is an acute hospital trust which, until 2019, operated Fairfield General Hospital in Bury, North Manchester General Hospital, the Royal Oldham Hospital and Rochdale Infirmary, all in Greater Manchester. It is now part of the Northern Care Alliance NHS Group. North Manchester General Hospital was formally acquired by Manchester University NHS Foundation Trust on April 1st 2021.It should not to be confused with Pennine Care NHS Foundation Trust, which is also based in Greater Manchester.
Purpose Intra-operative anterior cruciate ligament (ACL) graft contamination is a rare but recognised complication. There are no guidelines or consensus on the management of this occurrence. Our aim was to survey trauma and orthopaedic surgeons with a knee subspecialty interest in the United Kingdom (UK) who perform ACL reconstruction (ACLR) to explore the preferred strategy when there is intra-operative graft contamination. Methods An online questionnaire was sent to UK ACLR surgeons. The survey included the year of training completion, the average number of ACLs per year, whether they have experienced any intra-operative graft contamination, the strategies implemented, and whether they are aware of any literature and how it has influenced their strategies. Results Twenty-eight responses were received, with an average of 11 years of experience in ACLR, totalling an estimated of more than 15,000 ACLR. Three surgeons surveyed had experienced a single intra-operative ACL graft contamination, all of which were soaked in chlorhexidine gluconate (CG) solution. Of those surgeons who had not encountered a contaminated graft, 11 (44%) would use CG, 7 (28%) would soak in saline and vancomycin solution, and 7 (28%) would harvest a new graft. Conclusions There is significant variation in management strategy for an intra-operative contaminated graft in ACLR. This variation highlights the need for further work to develop a consensus for guidance for ACLR surgeons.
The effect of involved margins after breast cancer surgery on distant recurrence (DR) is unknown. We determined the association between margin width or involvement, DR and cancer deaths. PATIENTS AND METHODS:Greater Manchester (GM) and the National Cancer Registry (NCRAS) cohorts were analysed. Margin status after curative surgery was measured. Cox-proportional hazards investigated factors associated with LR, DR and breast cancer deaths. RESULTS:In GM (2010-2014), 2295 (70.2%) patients had clear margins ( > 2 mm), 302 (9.2%) close (1-2 mm) and 673 (20.6%) involved ( < 1 mm) margins. 2030 patients underwent breast conservation surgery (BCS). After multivariable adjustment in BCS patients, involved margins had an increased hazard of DR (HR 1.73, 95% CI:1.03, 2.88, p = 0.037) and LR (HR 2.16, 95% CI:1.31, 3.58, p = 0.003). NCRAS data from 2010-2013 in 16,420 BCS patients included 3,913 patients (23.9%) with final margins <1 mm. There were 642 deaths (3.9%) after 80.2 months median follow-up: 5.6% in patients with final margins <1 mm and 3.4% with margins >1 mm. After BCS, in 5246 patients who underwent chemotherapy after BCS, involved margins <1 mm had a HR of 1.33 (CI 1.10-1.60, p = 0.003) for cancer death. CONCLUSIONS:Margins >1 mm were associated with lower DR and cancer deaths. Guidelines should recommend a minimum margin clearance of 1 mm.
[This corrects the article DOI: 10.1016/j.ekir.2022.01.1054.].
Importance:Staphylococcus aureus surgical site infections (SSIs) and bloodstream infections (BSIs) are important complications of surgical procedures for which prevention remains suboptimal. Contemporary data on the incidence of and etiologic factors for these infections are needed to support the development of improved preventive strategies. Objectives:To assess the occurrence of postoperative S aureus SSIs and BSIs and quantify its association with patient-related and contextual factors. Design, Setting, and Participants:This multicenter cohort study assessed surgical patients at 33 hospitals in 10 European countries who were recruited between December 16, 2016, and September 30, 2019 (follow-up through December 30, 2019). Enrolled patients were actively followed up for up to 90 days after surgery to assess the occurrence of S aureus SSIs and BSIs. Data analysis was performed between November 20, 2020, and April 21, 2022. All patients were 18 years or older and had undergone 11 different types of surgical procedures. They were screened for S aureus colonization in the nose, throat, and perineum within 30 days before surgery (source population). Both S aureus carriers and noncarriers were subsequently enrolled in a 2:1 ratio. Exposure:Preoperative S aureus colonization. Main Outcomes and Measures:The main outcome was cumulative incidence of S aureus SSIs and BSIs estimated for the source population, using weighted incidence calculation. The independent association of candidate variables was estimated using multivariable Cox proportional hazards regression models. Results:In total, 5004 patients (median [IQR] age, 66 [56-72] years; 2510 [50.2%] female) were enrolled in the study cohort; 3369 (67.3%) were S aureus carriers. One hundred patients developed S aureus SSIs or BSIs within 90 days after surgery. The weighted cumulative incidence of S aureus SSIs or BSIs was 2.55% (95% CI, 2.05%-3.12%) for carriers and 0.52% (95% CI, 0.22%-0.91%) for noncarriers. Preoperative S aureus colonization (adjusted hazard ratio [AHR], 4.38; 95% CI, 2.19-8.76), having nonremovable implants (AHR, 2.00; 95% CI, 1.15-3.49), undergoing mastectomy (AHR, 5.13; 95% CI, 1.87-14.08) or neurosurgery (AHR, 2.47; 95% CI, 1.09-5.61) (compared with orthopedic surgery), and body mass index (AHR, 1.05; 95% CI, 1.01-1.08 per unit increase) were independently associated with S aureus SSIs and BSIs. Conclusions and Relevance:In this cohort study of surgical patients, S aureus carriage was associated with an increased risk of developing S aureus SSIs and BSIs. Both modifiable and nonmodifiable etiologic factors were associated with this risk and should be addressed in those at increased S aureus SSI and BSI risk.
Introduction In the past 5 years, there have been several advances in the management of inflammatory bowel disease (IBD). We aim for a new guideline to update the most recent guideline published in 2019. We present the prospective operating procedure and technical summary protocol in the manuscript. Methods ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) will be followed in the development of the guideline, approach as laid out in the GRADE handbook, supported by the WHO. The guideline development group is formed by a variety of disciplines, across both primary and secondary care that took part in an online Delphi process and split into key areas. A final consensus list of thematic questions within a ‘patient, intervention, comparison, outcome’ format has been produced and agreed in the final phase of the Delphi process. There will be a detailed technical evidence review with source data including systematic reviews appraised with AMSATAR 2 tool (Assessment of multiple systematic reviews), randomised controlled trial data that will be judged for risk of bias with the Cochrane tool and observational studies for safety concerns assessed through the Robins-I tool. Based on the available evidence, some of the recommendations will be based on GRADE while others will be best practice statements. A full Delphi process will be used to make recommendations using online response systems. This set of procedures has been approved by the Clinical Services and Standards Committee, the British Society of Gastroenterology executive board and aligned with IBD UK standards.